Hiroko Tanaka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hiroko Tanaka has a total of 513 co-authors. Here are the top co-authors by number of shared publications:
- Seishi Ogawa
Department of Pathology and Tumor Biology, Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan
23 shared publications - Satoru Miyano
M&D Data Science Center, Institute of Integrated Research, Institute of Science Tokyo
17 shared publications Yuichi Shiraishi
17Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
17 shared publicationsKenichi Chiba
17Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
15 shared publications- Kenichi Yoshida
Division of Cancer Evolution, National Cancer Center Research Institute, Tokyo, Japan
15 shared publications - Akifumi Takaori-Kondo
Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
13 shared publications
Latest Publications
- Open Access
- 21 April 2026
- Published by Springer Nature in Research Square
Diploid telomere-to-telomere assemblies reveal hierarchical satellite architectures and heritable MHC structural diversity in macaques
The crab-eating macaque (Macaca fascicularis), a key biomedical model, exhibits substantial inter-individual variability. However, its genomic architecture remains incompletely resolved due to extensive structural complexity and reliance on haploid reference assemblies. Here, we generated 24 diploid telomere-to-telomere (T2T) haplotypes from 12 male and female individuals representing three geographic populations including a pedigree, enabling systematic interrogation of genome architecture at diploid resolution with geographic diversity and familial inheritance. We identified previously uncharacterized large inter-chromosomal repeat clusters with haplotype-specific organization that are conserved among old world monkeys. In addition, twenty-four completely contiguous major histocompatibility complex (MHC) haplotypes reveal extensive inter or intra individual variations in gene copy number and structural organization of the class-IA, IB, and II regions. Together, these findings demonstrate that diploid T2T assemblies are essential for accurately capturing structural and immunogenetic diversity in non-human primates and provide a genomic framework for precision immunogenomics in this widely used biomedical model.
- 21 April 2026
- Published by Springer Nature in Research Square
Open AccessDiploid telomere-to-telomere assemblies reveal hierarchical satellite architectures and heritable MHC structural diversity in macaques
The crab-eating macaque (Macaca fascicularis), a key biomedical model, exhibits substantial inter-individual variability. However, its genomic architecture remains incompletely resolved due to extensive structural complexity and reliance on haploid reference assemblies. Here, we generated 24 diploid telomere-to-telomere (T2T) haplotypes from 12 male and female individuals representing three geographic populations including a pedigree, enabling systematic interrogation of genome architecture at diploid resolution with geographic diversity and familial inheritance. We identified previously uncharacterized large inter-chromosomal repeat clusters with haplotype-specific organization that are conserved among old world monkeys. In addition, twenty-four completely contiguous major histocompatibility complex (MHC) haplotypes reveal extensive inter or intra individual variations in gene copy number and structural organization of the class-IA, IB, and II regions. Together, these findings demonstrate that diploid T2T assemblies are essential for accurately capturing structural and immunogenetic diversity in non-human primates and provide a genomic framework for precision immunogenomics in this widely used biomedical model.
- Open Access
- 26 March 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (13) , 1395-1411
Comprehensive molecular and functional analysis of NUTM1 -rearranged leukemia
NUTM1 rearrangement defines a significant subset of B-cell acute lymphoblastic leukemia (B-ALL), particularly in infants lacking KMT2A rearrangements, yet its underlying molecular characteristics remain poorly understood. Here, we establish that NUTM1-rearranged (NUTM1-r) leukemia is a discrete entity characterized by a unique transcriptional and epigenetic landscape, notably featuring global DNA hypomethylation, irrespective of the 5′ fusion partner. Functional interrogation of NUTM1 fusions reveals a dual oncogenic role: they drive commitment toward the B-lymphoid lineage while concurrently conferring potent leukemic stem cell properties. Strikingly, expression of a representative fusion, BRD9-NUTM1, is sufficient to induce serially transplantable B-cell progenitor, prepro–B-like leukemia in vivo, faithfully recapitulating the key molecular and immunophenotypic features of human NUTM1-r B-ALL. Mechanistically, NUTM1 fusions establish an aberrant chromatin state, marked by global enhancement of H3K27 acetylation and the creation of distinctive open chromatin regions that co-opt both B-lineage and stemness-related transcriptional programs, including those involving NF-κB and posterior HoxA genes. In stark contrast to resistant KMT2A-rearranged leukemias, NUTM1-r leukemic cells exhibit a profound sensitivity to chemotherapy. This vulnerability is mechanistically linked to the leukemia's dependence on active transcription. Our findings delineate the unique molecular profile of NUTM1-r leukemias, revealing specific vulnerabilities that rationalize their favorable clinical outcomes and suggest opportunities for modified therapeutic strategies.
- 26 March 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (13) , 1395-1411
Open AccessComprehensive molecular and functional analysis of NUTM1 -rearranged leukemia
NUTM1 rearrangement defines a significant subset of B-cell acute lymphoblastic leukemia (B-ALL), particularly in infants lacking KMT2A rearrangements, yet its underlying molecular characteristics remain poorly understood. Here, we establish that NUTM1-rearranged (NUTM1-r) leukemia is a discrete entity characterized by a unique transcriptional and epigenetic landscape, notably featuring global DNA hypomethylation, irrespective of the 5′ fusion partner. Functional interrogation of NUTM1 fusions reveals a dual oncogenic role: they drive commitment toward the B-lymphoid lineage while concurrently conferring potent leukemic stem cell properties. Strikingly, expression of a representative fusion, BRD9-NUTM1, is sufficient to induce serially transplantable B-cell progenitor, prepro–B-like leukemia in vivo, faithfully recapitulating the key molecular and immunophenotypic features of human NUTM1-r B-ALL. Mechanistically, NUTM1 fusions establish an aberrant chromatin state, marked by global enhancement of H3K27 acetylation and the creation of distinctive open chromatin regions that co-opt both B-lineage and stemness-related transcriptional programs, including those involving NF-κB and posterior HoxA genes. In stark contrast to resistant KMT2A-rearranged leukemias, NUTM1-r leukemic cells exhibit a profound sensitivity to chemotherapy. This vulnerability is mechanistically linked to the leukemia's dependence on active transcription. Our findings delineate the unique molecular profile of NUTM1-r leukemias, revealing specific vulnerabilities that rationalize their favorable clinical outcomes and suggest opportunities for modified therapeutic strategies.
- Open Access
- 6 May 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (9) , 4412
Unraveling the COVID-19 Severity Hubs and Interplays in Inflammatory-Related RNA–Protein Networks
The rapid worldwide transmission of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to severe cases of hypoxia, acute respiratory distress syndrome, multi-organ failure, and ultimately death. Small-scale molecular interactions have been analyzed by focusing on several genes/single genes, providing important insights; however, genome-wide multi-omics comprehensive molecular interactions have not yet been well investigated with the exception of GWAS and eQTLm, both of which show genetic risks. From April of 2020 until now, we have created a Japan-wide system, initially named the Japan COVID-19 Task Force. This system has collected more than 6500 COVID-19 patients’ peripheral blood and as much associated clinical information as possible from a network of more than 120 hospitals. DNA, RNA, serum, and plasma were extracted and stored in this bank. This study unravels the interplay of inflammatory gene networks that induce different COVID-19 severity levels (mild, moderate, severe, and critical) by using multi-omics data from the Japan COVID-19 Task Force. We analyze RNA and protein expressions to estimate severity-specific inflammation networks that uncover the interplay between RNA and protein networks via ligand–receptor pairs. Our large-scale RNA/protein expression data analysis reveals that the atypical chemokine receptor 2 (ACKR2) acts as a key broker linking RNA and protein inflammation networks to induce COVID-19 critical severity. ACKR2 emerges in RNA and protein inflammation networks, showing active interplay in high-severity cases and weak interactions in mild cases. The results also show severity-specific molecular interactions between interleukin (IL), cytokine receptor activity, cell adhesion, and interactions involving the CC chemokine ligand (CCL) gene family and ACKR2.
- 6 May 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (9) , 4412
Open AccessUnraveling the COVID-19 Severity Hubs and Interplays in Inflammatory-Related RNA–Protein Networks
The rapid worldwide transmission of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to severe cases of hypoxia, acute respiratory distress syndrome, multi-organ failure, and ultimately death. Small-scale molecular interactions have been analyzed by focusing on several genes/single genes, providing important insights; however, genome-wide multi-omics comprehensive molecular interactions have not yet been well investigated with the exception of GWAS and eQTLm, both of which show genetic risks. From April of 2020 until now, we have created a Japan-wide system, initially named the Japan COVID-19 Task Force. This system has collected more than 6500 COVID-19 patients’ peripheral blood and as much associated clinical information as possible from a network of more than 120 hospitals. DNA, RNA, serum, and plasma were extracted and stored in this bank. This study unravels the interplay of inflammatory gene networks that induce different COVID-19 severity levels (mild, moderate, severe, and critical) by using multi-omics data from the Japan COVID-19 Task Force. We analyze RNA and protein expressions to estimate severity-specific inflammation networks that uncover the interplay between RNA and protein networks via ligand–receptor pairs. Our large-scale RNA/protein expression data analysis reveals that the atypical chemokine receptor 2 (ACKR2) acts as a key broker linking RNA and protein inflammation networks to induce COVID-19 critical severity. ACKR2 emerges in RNA and protein inflammation networks, showing active interplay in high-severity cases and weak interactions in mild cases. The results also show severity-specific molecular interactions between interleukin (IL), cytokine receptor activity, cell adhesion, and interactions involving the CC chemokine ligand (CCL) gene family and ACKR2.
- Open Access
- 17 March 2025
- Published by Springer Nature in Research Square
PRDM16::SKI is a predictor of aberrant expression of the short variant of PRDM16 in pediatric acute myeloid leukemia
The RNA-sequencing data from the Japanese Children’s Cancer Group (JCCG)’s AML-05 study was re-analyzed to clarify the mechanisms related to high PRDM16 expressions, which is independently associated with adverse outcomes. Results showed that 19 of 139 patients presented with out-of-frame PRDM16::SKI fusions. Thus, the gene expression levels of PRDM16::SKI in 369 and 329 patients from the AML-05 and AML-12 studies, respectively, were measured. In total, 119 (32%) of 369 patients in the AML-05 study and 58 (18%) of 329 patients in the AML-12 study presented with an aberrant expression of PRDM16::SKI. This fusion was a 48-base-pair product that immediately formed a stop codon on the SKI side. The introduction of this product in mice did not cause AML. Intriguingly, none of the patients presented with SKI::PRDM16, which is reciprocal. Moreover, partner fusion genes were not detected in front of truncated PRDM16, indicating that a short form of PRDM16, which lacked exon 1, existed by itself. Patients with high PRDM16::SKI expression had significantly worse overall survival and event-free survival than those with a low PRDM16 expression. The cleavage between exons 1 and 2 of PRDM16 induces aberrant PRDM16 expression, and a strong associations was observed between PRDM16::SKI and PRDM16 expression.
- 17 March 2025
- Published by Springer Nature in Research Square
Open AccessPRDM16::SKI is a predictor of aberrant expression of the short variant of PRDM16 in pediatric acute myeloid leukemia
The RNA-sequencing data from the Japanese Children’s Cancer Group (JCCG)’s AML-05 study was re-analyzed to clarify the mechanisms related to high PRDM16 expressions, which is independently associated with adverse outcomes. Results showed that 19 of 139 patients presented with out-of-frame PRDM16::SKI fusions. Thus, the gene expression levels of PRDM16::SKI in 369 and 329 patients from the AML-05 and AML-12 studies, respectively, were measured. In total, 119 (32%) of 369 patients in the AML-05 study and 58 (18%) of 329 patients in the AML-12 study presented with an aberrant expression of PRDM16::SKI. This fusion was a 48-base-pair product that immediately formed a stop codon on the SKI side. The introduction of this product in mice did not cause AML. Intriguingly, none of the patients presented with SKI::PRDM16, which is reciprocal. Moreover, partner fusion genes were not detected in front of truncated PRDM16, indicating that a short form of PRDM16, which lacked exon 1, existed by itself. Patients with high PRDM16::SKI expression had significantly worse overall survival and event-free survival than those with a low PRDM16 expression. The cleavage between exons 1 and 2 of PRDM16 induces aberrant PRDM16 expression, and a strong associations was observed between PRDM16::SKI and PRDM16 expression.
- 20 June 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (25) , 2627-2643
Landscape of driver mutations and their clinical effects on Down syndrome–related myeloid neoplasms
Transient abnormal myelopoiesis (TAM) is a common complication in newborns with Down syndrome (DS). It commonly progresses to myeloid leukemia (ML-DS) after spontaneous regression. In contrast to the favorable prognosis of primary ML-DS, patients with refractory/relapsed ML-DS have poor outcomes. However, the molecular basis for refractoriness and relapse and the full spectrum of driver mutations in ML-DS remain largely unknown. We conducted a genomic profiling study of 143 TAM, 204 ML-DS, and 34 non-DS acute megakaryoblastic leukemia cases, including 39 ML-DS cases analyzed by exome sequencing. Sixteen novel mutational targets were identified in ML-DS samples. Of these, inactivations of IRX1 (16.2%) and ZBTB7A (13.2%) were commonly implicated in the upregulation of the MYC pathway and were potential targets for ML-DS treatment with bromodomain-containing protein 4 inhibitors. Partial tandem duplications of RUNX1 on chromosome 21 were also found, specifically in ML-DS samples (13.7%), presenting its essential role in DS leukemia progression. Finally, in 177 patients with ML-DS treated following the same ML-DS protocol (the Japanese Pediatric Leukemia and Lymphoma Study Group acute myeloid leukemia -D05/D11), CDKN2A, TP53, ZBTB7A, and JAK2 alterations were associated with a poor prognosis. Patients with CDKN2A deletions (n = 7) or TP53 mutations (n = 4) had substantially lower 3-year event-free survival (28.6% vs 90.5%; P < .001; 25.0% vs 89.5%; P < .001) than those without these mutations. These findings considerably change the mutational landscape of ML-DS, provide new insights into the mechanisms of progression from TAM to ML-DS, and help identify new therapeutic targets and strategies for ML-DS.
- 20 June 2024
- Published by American Society of Hematology in Blood
- Vol. 143 (25) , 2627-2643
Landscape of driver mutations and their clinical effects on Down syndrome–related myeloid neoplasms
Transient abnormal myelopoiesis (TAM) is a common complication in newborns with Down syndrome (DS). It commonly progresses to myeloid leukemia (ML-DS) after spontaneous regression. In contrast to the favorable prognosis of primary ML-DS, patients with refractory/relapsed ML-DS have poor outcomes. However, the molecular basis for refractoriness and relapse and the full spectrum of driver mutations in ML-DS remain largely unknown. We conducted a genomic profiling study of 143 TAM, 204 ML-DS, and 34 non-DS acute megakaryoblastic leukemia cases, including 39 ML-DS cases analyzed by exome sequencing. Sixteen novel mutational targets were identified in ML-DS samples. Of these, inactivations of IRX1 (16.2%) and ZBTB7A (13.2%) were commonly implicated in the upregulation of the MYC pathway and were potential targets for ML-DS treatment with bromodomain-containing protein 4 inhibitors. Partial tandem duplications of RUNX1 on chromosome 21 were also found, specifically in ML-DS samples (13.7%), presenting its essential role in DS leukemia progression. Finally, in 177 patients with ML-DS treated following the same ML-DS protocol (the Japanese Pediatric Leukemia and Lymphoma Study Group acute myeloid leukemia -D05/D11), CDKN2A, TP53, ZBTB7A, and JAK2 alterations were associated with a poor prognosis. Patients with CDKN2A deletions (n = 7) or TP53 mutations (n = 4) had substantially lower 3-year event-free survival (28.6% vs 90.5%; P < .001; 25.0% vs 89.5%; P < .001) than those without these mutations. These findings considerably change the mutational landscape of ML-DS, provide new insights into the mechanisms of progression from TAM to ML-DS, and help identify new therapeutic targets and strategies for ML-DS.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia
Supplementary Table from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia
Supplementary Table from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia
Supplementary Figure from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia
Supplementary Figure from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia
Supplementary Figure from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia
Supplementary Figure from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia
Acute erythroid leukemia (AEL) is a unique subtype of acute myeloid leukemia characterized by prominent erythroid proliferation whose molecular basis is poorly understood. To elucidate the underlying mechanism of erythroid proliferation, we analyzed 121 AEL using whole-genome, whole-exome, and/or targeted-capture sequencing, together with transcriptome analysis of 21 AEL samples. Combining publicly available sequencing data, we found a high frequency of gains and amplifications involving EPOR/JAK2 in TP53-mutated cases, particularly those having >80% erythroblasts designated as pure erythroid leukemia (10/13). These cases were frequently accompanied by gains and amplifications of ERG/ETS2 and associated with a very poor prognosis, even compared with other TP53-mutated AEL. In addition to activation of the STAT5 pathway, a common feature across all AEL cases, these AEL cases exhibited enhanced cell proliferation and heme metabolism and often showed high sensitivity to ruxolitinib in vitro and in xenograft models, highlighting a potential role of JAK2 inhibition in therapeutics of AEL.Significance:This study reveals the major role of gains, amplifications, and mutations of EPOR and JAK2 in the pathogenesis of pure erythroleukemia. Their frequent response to ruxolitinib in patient-derived xenograft and cell culture models highlights a possible therapeutic role of JAK2 inhibition for erythroleukemia with EPOR/JAK2-involving lesions.This article is highlighted in the In This Issue feature, p. 369
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia
Acute erythroid leukemia (AEL) is a unique subtype of acute myeloid leukemia characterized by prominent erythroid proliferation whose molecular basis is poorly understood. To elucidate the underlying mechanism of erythroid proliferation, we analyzed 121 AEL using whole-genome, whole-exome, and/or targeted-capture sequencing, together with transcriptome analysis of 21 AEL samples. Combining publicly available sequencing data, we found a high frequency of gains and amplifications involving EPOR/JAK2 in TP53-mutated cases, particularly those having >80% erythroblasts designated as pure erythroid leukemia (10/13). These cases were frequently accompanied by gains and amplifications of ERG/ETS2 and associated with a very poor prognosis, even compared with other TP53-mutated AEL. In addition to activation of the STAT5 pathway, a common feature across all AEL cases, these AEL cases exhibited enhanced cell proliferation and heme metabolism and often showed high sensitivity to ruxolitinib in vitro and in xenograft models, highlighting a potential role of JAK2 inhibition in therapeutics of AEL.Significance:This study reveals the major role of gains, amplifications, and mutations of EPOR and JAK2 in the pathogenesis of pure erythroleukemia. Their frequent response to ruxolitinib in patient-derived xenograft and cell culture models highlights a possible therapeutic role of JAK2 inhibition for erythroleukemia with EPOR/JAK2-involving lesions.This article is highlighted in the In This Issue feature, p. 369